Mode of Action of the Amaryllidaceae Alkaloid Lycorine-Promising Anticancer Agent
Mode of Action of the Amaryllidaceae Alkaloid Lycorine-Promising Anticancer Agent
批准号:
8763979
负责人:
ALEXANDER KORNIENKO
金额:
$47.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-15 至 2017-06-30
关键词:
ActinsAlkaloidsAlkynesAmaryllidaceae AlkaloidsAntineoplastic AgentsApoptosisApoptoticAvidinBackBindingBinding ProteinsBiologicalBiological AssayBiological FactorsBiologyBiotinBrainBrain NeoplasmsCancer PatientCancer cell lineCell LineChemicalsComputersCytoskeletonDataDevelopmentDoseEvaluationExhibitsFoundationsFutureGlioblastomaGliomaGoalsInduction of ApoptosisInvestigationKnowledgeMalignant NeoplasmsMelanoma CellModelingMusNeoplasm MetastasisNon-Small-Cell Lung CarcinomaNormal CellOutcomePharmaceutical PreparationsPhotoaffinity LabelsPreparationProbabilityPropertyProteinsRelative (related person)ResearchResistanceSiteSolidStimulusStructureTherapeuticTimeValidationWorkanalogbasecancer cellcancer therapycancer typedesigndrug discoveryexperienceimprovedin vivoinnovationmelanomamigrationmouse modelneoplastic cellnovelnovel strategiesnovel therapeuticsoutcome forecastpharmacophorepublic health relevancetreatment strategytumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The ultimate goal of this project is the development of a novel therapeutic strategy for the treatment of cancer capitalizing on the unique antiproliferative effects of the alkaloid lycorine on apoptosis resistant cancers. Although a large
majority of current cancer drugs exhibit their effects through the induction of apoptosis in tumor cells, many types of cancer, such as glioma, melanoma, NSCLC, among others, are resistant to proapoptotic stimuli and are typically associated with dismal prognoses. Therefore, new chemotypes that display antiproliferative effects against such apoptosis-resistant cancers and/or inhibit tumor metastatic spread are urgently needed. In preliminary work, the PI's collaborative chemical biology/drug discovery team has shown that the alkaloid lycorine modifies actin cytoskeleton organization in cancer cells, and impairs both their proliferation and migration. Lycorine exerts these effects with both apoptotic-resistant and susceptible cell lines, sensitizes cancer cells to proapoptotic agents, and displays 15 times greater potency toward cancer versus normal cells. Furthermore, lycorine showed significant therapeutic benefit in vivo in the B16F10 mouse melanoma model, consisting of orthotopically brain-grafted melanoma cells. These preliminary results form a compelling case for a thorough understanding of lycorine's mode of action in cancer cells and utilization of this knowledge for the development of novel strategies to treat cancers with dismal prognoses. The proposed work involves the preparation of lycorine- alkyne probes, which will be evaluated against a panel of apoptosis-resistant cancer cells with the goal of identifying derivatives retaining the antiproliferative potency and mode of action of lycorine. Suitable alkyne probes will then be used in protein pull-down assays, aimed at target protein identification. Several back-up target identification and target validation strategies are also proposed to confirm this innovative chemotherapeutic approach.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3390/molecules23020255
发表时间:
2018-01-28
期刊:
Molecules (Basel, Switzerland)
影响因子:
--
作者:
[Govindaraju K, Masi M, Colin M, Mathieu V, Evidente A, Hudnall TW, Kornienko A]
通讯作者:
Kornienko A
DOI:
10.1039/c7np00024c
发表时间:
2017-08-30
期刊:
Natural product reports
影响因子:
11.9
作者:
[Kornienko A, La Clair JJ]
通讯作者:
La Clair JJ
DOI:
10.1002/med.21423
发表时间:
2017-07
期刊:
Medicinal research reviews
影响因子:
13.3
作者:
[Ciavatta ML, Lefranc F, Carbone M, Mollo E, Gavagnin M, Betancourt T, Dasari R, Kornienko A, Kiss R]
通讯作者:
Kiss R
DOI:
10.1021/acs.jnatprod.5b00779
发表时间:
2016-01-22
期刊:
Journal of natural products
影响因子:
5.1
作者:
[Cimmino A, Mathieu V, Masi M, Baroncelli R, Boari A, Pescitelli G, Ferderin M, Lisy R, Evidente M, Tuzi A, Zonno MC, Kornienko A, Kiss R, Evidente A]
通讯作者:
Evidente A
DOI:
10.2174/0929867322666150821101047
发表时间:
2015
期刊:
Current medicinal chemistry
影响因子:
4.1
作者:
[Evidente A, Kornienko A, Lefranc F, Cimmino A, Dasari R, Evidente M, Mathieu V, Kiss R]
通讯作者:
Kiss R
共 11 条
Tandem Discovery of Drug Leads and Targets via Paal-Knorr reaction
-
批准号:10004127
-
项目类别:
-
资助金额:$16.21万
-
财政年份:2019
-
负责人:ALEXANDER KORNIENKO
-
依托单位:
ELUCIDATION OF THE PANCRATISTATIN CYTOTOXIC PHARMACOPHORE
-
批准号:7960231
-
项目类别:
-
资助金额:$12.87万
-
财政年份:2009
-
负责人:ALEXANDER KORNIENKO
-
依托单位:
ELUCIDATION OF THE PANCRATISTATIN CYTOTOXIC PHARMACOPHORE
-
批准号:7720456
-
项目类别:
-
资助金额:$12.62万
-
财政年份:2008
-
负责人:ALEXANDER KORNIENKO
-
依托单位:
ELUCIDATION OF THE PANCRATISTATIN CYTOTOXIC PHARMACOPHORE
-
批准号:7610367
-
项目类别:
-
资助金额:$7.32万
-
财政年份:2007
-
负责人:ALEXANDER KORNIENKO
-
依托单位:
ELUCIDATION OF THE PANCRATISTATIN CYTOTOXIC PHARMACOPHORE
-
批准号:7381756
-
项目类别:
-
资助金额:$7.48万
-
财政年份:2006
-
负责人:ALEXANDER KORNIENKO
-
依托单位:
ELUCIDATION OF THE PANCRATISTATIN CYTOTOXIC PHARMACOPHORE
-
批准号:7170976
-
项目类别:
-
资助金额:$7.84万
-
财政年份:2005
-
负责人:ALEXANDER KORNIENKO
-
依托单位:
Enantiodivergent Synthesis of (+) and (-) Pancratistatin
-
批准号:6593475
-
项目类别:
-
资助金额:$14.47万
-
财政年份:2003
-
负责人:ALEXANDER KORNIENKO
-
依托单位:
Enantiodivergent Synthesis of (+) and (-) Pancratistatin
-
批准号:6896624
-
项目类别:
-
资助金额:$19.56万
-
财政年份:2003
-
负责人:ALEXANDER KORNIENKO
-
依托单位:
国内基金
海外基金
Iboga alkaloids骨架导向的不对称串联反应构建吖庚环并[4,5-b]吲哚及其在全合成中的应用
-
批准号:21801032
-
项目类别:青年科学基金项目
-
资助金额:26.0万元
-
批准年份:2018
-
负责人:陈惠渝
-
依托单位: